3 ‘Perfect 10’ Growth Stocks That Could Hit New Highs

 | Jul 15, 2021 18:14

The buzz lately has been all about growth. Stocks are high, and going higher. The gains we’re seeing now are the current extension of a long-term trend – markets have been rising for several years, and their derailment during last year’s corona crisis appears, in hindsight, to have been a blip more than anything else.

As President Kennedy said long ago, a rising tide lifts all boats – and right now, a savvy investor can find plenty of boats to jump on.

So let’s go find some of those rising boats. Using ‘Perfect 10’ smart score. Let’s take a closer look.

Evolent Health ( )

We’ll start in the healthcare industry, where Evolent Health (NYSE:EVH) is a service company to the medical providers. Evolent offers administrative and clinical services to the payers and providers in the healthcare system, working to push down costs while keeping up the quality of care. Evolent’s services include core administration, actuarial services, risk adjustment, pharmacy benefit management, medical and behavioral health integration, and an integrated technology platform to track it all efficiently.

Evolent saw steep EPS losses at the end of 2019 and the beginning of 2020, coinciding with the worst of the corona crisis – but losses have been moderating in recent quarters. For the most recent report, 1Q21, the company showed a 12-cent net loss per share – but that was much improved from the year-ago quarter’s EPS loss of 93 cents.

During the first quarter, Evolent announced several new partnerships with healthcare providers, including a network of primary care clinics. The company’s platform currently has over 11.6 million patients’ data under management.

Evolent shares have raced ahead 195% over the past 52 weeks, but would you believe it could go up another 35%? Truist analyst Sandy Draper does. The analyst rates EVH a Buy along with a $31 price target.

“We continue to believe EVH can grow its top line at 15%-20% annually and achieve positive EBITDA margin expansion. Recent wins including Florida Blue are driving growth this year and new wins in 1Q21 (including a large unnamed health plan) should drive growth in 2022. We think the current valuation does not reflect the improving growth dynamics and de-risked balance sheet,” the 5-star analyst opined.

Draper went on to enumerate several key advantages Evolent offers for market investors: “We view Evolent as a unique play on the transformative shift from the current fee for service environment to value based care in the U.S… We believe that Evolent is differentiated by its proprietary underlying technology platform called Identifi, expertise… and proven track record with existing customers.”

Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now

Overall, this stock has 5 recent analyst reviews on file, and they break down 4 to 1 in favor the Buys over the Hold. The shares are currently trading for $22.79 and have an average price target of $26.80, giving the stock an upside potential of ~18%. (See EVH stock analysis )